NCT04189757View on ClinicalTrials.gov

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER